An Open-Label Multicenter Study Administering Lapatinib and Capecitabine (Xeloda) in Women With Advanced or Metastatic Breast Cancer
Latest Information Update: 18 Jul 2023
At a glance
- Drugs Capecitabine (Primary) ; Lapatinib (Primary)
- Indications Advanced breast cancer; Cancer metastases; Early breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK; Novartis Pharmaceuticals
- 26 Aug 2021 Status changed from completed to discontinued due to primary analysis was completed in 2015 and data collection post 1-Jul-2019 was not reportabledue to local regulations in China. .
- 13 Jul 2020 Status changed from active, no longer recruiting to completed.
- 14 Apr 2020 Planned End Date changed from 20 Dec 2021 to 30 Apr 2020.